
AMENDED CLAIMS
received by the International Bureau on 09 May 2012 (09.05.2012)

1. A compound of Formula I



I

or a pharmaceutically acceptable salt thereof, wherein

R^1 is phenyl substituted with halo or trifluoromethyl ;
or a 6-membered heteroaryl group which is optionally fused with a (C_4-C_7)cycloalkyl, phenyl or 5 to 6 membered heteroaryl, and wherein the optionally fused 6-membered heteroaryl group is optionally substituted with one to four substituents each independently selected from halo, -S(O)$_2$-(C_{1-3})alkyl, hydroxy, -C(O)NR^aR^b, cyano, (C_1-C_6)alkyl optionally substituted with one to three fluoro, or (C_1-C_6)alkoxy optionally substituted with one to three fluoro;

R^a and R^b are each independently H or (C_1-C_3)alkyl;

R^2 is H ;

R^3 is –$(CH_2)_2CO_2H$;

A^1, A^2, A^3 and A^4 are each independently CR^4 or N, with the proviso that one or two of A^1, A^2, A^3 and A^4 are N and further provided that A^2 and A^3 are not both N;

R^4 at each occurrence is independently H, halo, cyano, (C_1-C_3)alkyl optionally substituted with one to three fluoro, or (C_1-C_3)alkoxy optionally substituted with one to three fluoro;

L is -CH(R^5)-X-;

X is NH;

R^5 is (C_1-C_6)alkyl which is optionally substituted with one to three fluoro, hydroxy or methoxy; (C_3-C_7)cycloalkyl which is optionally substituted with one to two (C_1-C_3)alkyl which are optionally substituted with one to three fluoro or one to two (C_1-C_3)alkyl and wherein one to two carbons of the (C_3-C_7)cycloalkyl can be replaced with a NH, N(C_1-C_3)alkyl, O or S; or (C_3-C_7)cycloalkyl-(C_1-C_6)alkyl wherein the (C_3-C_7)cycloalkyl group of

said (C_3-C_7)cycloalkyl-(C_1-C_6)alkyl is optionally substituted with one to two (C_1-C_3)alkyl which are optionally substituted with one to three fluoro;

B^1, B^2, B^3 and B^4 are each independently CR^6 or N, with the proviso that no more than two of B^1, B^2, B^3 and B^4 are N; and

R^6 at each occurrence is independently H, halo, (C_1-C_3)alkyl optionally substituted with one to three fluoro, or (C_1-C_3)alkoxy optionally substituted with one to three fluoro.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R^5 is ethyl, propyl, isopropyl, isobutyl, t-butyl, pentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclopropylmethyl each optionally substituted with 1 to 3 fluoro and wherein said cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl are each optionally substituted with 1 to 2 methyl.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R^1 is 4-trifluoromethylphenyl or 4-chlorophenyl; and R^4 and R^6 at each occurrence are H.

4. The compound of claim 3 or a pharmaceutically acceptable salt thereof wherein B^1 is N and B^2, B^3 and B^4 are each CR^6; B^2 is N and B^1, B^3 and B^4 are each CR^6; B^1 and B^4 are each N and B^2 and B^3 are each CR^6; B^2 and B^3 are each N and B^1 and B^4 are each CR^6; or B^1 and B^3 are each N and B^2 and B^4 are each CR^6.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein A^1 is N and A^2, A^3 and A^4 are each CR^4; A^2 is N and A^1, A^3 and A^4 are each CR^4; A^1 and A^4 are each N and A^2 and A^3 are each CR^4; or A^1 and A^3 are each N and A^2 and A^4 are each CR^4.

6. 3-[(6-{(*S*)-3-methyl-1-[2-(4-trifluoromethyl-phenyl)-pyrimidin-5-yl]-butylamino}-pyridine-3-carbonyl)-amino]-propionic acid or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising (i) a compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, and (ii) a pharmaceutically acceptable excipient, diluent, or carrier.

8. The composition of claim 7 wherein said compound or said therapeutically acceptable salt thereof is present in a therapeutically effective amount.

9. The use of a compound of Claim 1 through Claim 6, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or delaying the progression or onset of Type 2 diabetes and diabetes-related disorders.

10. The use of a compound of Claim 1 through 6, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease, condition or disorder that is modulated by the deactivation of a glucagon receptor.

Claims

1. 3-[(6-{(*S*)-3-methyl-1-[2-(4-trifluoromethyl-phenyl)-pyrimidin-5-yl]-butylamino}-pyridine-3-carbonyl)-amino]-propionic acid or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising (i) the compound of claim 1, or a pharmaceutically acceptable salt thereof, and (ii) a pharmaceutically acceptable excipient, diluent, or carrier.

3. The composition of claim 2, wherein said compound or said therapeutically acceptable salt thereof is present in a therapeutically effective amount.

4. Use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or delaying the progression or onset of Type 2 diabetes and diabetes-related disorders.

5. The use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease, condition or disorder that is modulated by the deactivation of a glucagon receptor.